{"article_title": "If Pfizer's Right, Hospira Biosimilar Gold Rush Begins", "article_keywords": ["begins", "rush", "right", "gold", "hospira", "biosimilar", "pfizers"], "article_url": "http://www.forbes.com/sites/brucejapsen/2015/02/16/if-pfizers-right-hospira-biosimilar-gold-rush-begins-this-week/", "article_text": "", "article_metadata": {"prerender-status-code": "{{meta.code}}", "author": "Bruce Japsen", "og": {"site_name": "Forbes", "description": "Hospira (HSP), the injectable generic drug maker Pfizer (PFE) is buying for $90 a share, is making its biggest foray yet into the business of cheaper \u201cgeneric\u201d biologic drugs this week, launching the biosimilar to the pricey autoimmune drug Remicade in Europe. Hospira will begin selling Inflectra, also known as infliximab, [...]", "title": "If Pfizer's Right, Hospira Biosimilar Gold Rush Begins", "url": "http://www.forbes.com/sites/brucejapsen/2015/02/16/if-pfizers-right-hospira-biosimilar-gold-rush-begins-this-week/", "image": "http://blogs-images.forbes.com/brucejapsen/files/2015/02/98d336da0f13a2dece939a6a784d8f60_9957.jpg", "updated_time": "2015-02-18T00:03:13-05:00", "type": "article"}, "twitter": {"description": "Hospira (HSP), the injectable generic drug maker Pfizer (PFE) is buying for $90 a share, is making its biggest foray yet into the business of cheaper \u201cgeneric\u201d biologic drugs this week, launching the biosimilar to the pricey autoimmune drug Remicade in Europe. Hospira will begin selling Inflectra, also known as infliximab, [...]", "creator": "@brucejapsen", "image": "http://blogs-images.forbes.com/brucejapsen/files/2015/02/98d336da0f13a2dece939a6a784d8f60_9957.jpg", "title": "If Pfizer's Right, Hospira Biosimilar Gold Rush Begins", "site": "@forbes", "card": "summary_large_image"}, "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Business,Health,Healthcare Innovation,Lifestyle,Pharma and Health,Retail,Wall Street,Washington,Pharma &amp; Healthcare,The Economy", "article": {"publisher": "https://www.facebook.com/forbes", "section_url": "http://www.forbes.com/business", "section": "Business", "modified": "2015-02-18", "published": "2015-02-16", "id": "blogAndPostId/blog/post/2125-9957"}, "news_keywords": "Business,Health,Healthcare Innovation,Lifestyle,Pharma and Health,Retail,Wall Street,Washington,Pharma &amp; Healthcare,The Economy", "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "description": "Hospira (HSP), the injectable generic drug maker Pfizer (PFE) is buying for $90 a share, is making its biggest foray yet into the business of cheaper \u201cgeneric\u201d biologic drugs this week, launching the biosimilar to the pricey autoimmune drug Remicade in Europe. Hospira will begin selling Inflectra, also known as infliximab, [...]"}, "_id": "\"57477af46914bd0286fe15d7\"", "article_summary": ""}